Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Cultural competence and simulated patients.

Paroz S, Daele A, Viret F, Vadot S, Bonvin R, Bodenmann P.

Clin Teach. 2016 Jan 18. doi: 10.1111/tct.12466. [Epub ahead of print]

PMID:
26783081
2.

METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.

Launay S, Sabatier R, Brunelle S, Esterni B, Tarpin C, Viret F, Gravis G, Cappiello M, Provansal M, Extra JM, Bertucci F, Viens P, Goncalves A.

Anticancer Res. 2016 Jan;36(1):293-9.

PMID:
26722056
3.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A.

Lancet Oncol. 2015 Nov;16(15):1493-505. doi: 10.1016/S1470-2045(15)00216-8. Epub 2015 Oct 22. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

PMID:
26474518
4.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J; PETACC-8 Study Investigators.

Ann Oncol. 2014 Dec;25(12):2378-85. doi: 10.1093/annonc/mdu464. Epub 2014 Oct 6. Erratum in: Ann Oncol. 2015 Apr;26(4):822-5.

5.

Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.

Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, Peiffert D, Mornex F, Abbas M, Boige V, Pignon JP, Conroy T, Cellier P, Juzyna B, Viret F.

Dig Liver Dis. 2014 Oct;46(10):950-5. doi: 10.1016/j.dld.2014.06.006. Epub 2014 Jul 12.

PMID:
25027552
6.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators.

Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.

PMID:
24928083
7.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators.

Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.

PMID:
24852116
8.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups.

Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12.

9.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators.

Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.

PMID:
23168366
10.

Initial experience with hyperthermic intraperitoneal chemotherapy.

Turrini O, Lambaudie E, Faucher M, Viret F, Blache JL, Houvenaeghel G, Delpero JR.

Arch Surg. 2012 Oct;147(10):919-23. doi: 10.1001/archsurg.2012.988.

PMID:
23117830
11.

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F.

J Clin Oncol. 2012 Aug 10;30(23):2861-8. doi: 10.1200/JCO.2011.40.9243. Epub 2012 Jul 2.

12.

Contributing to research via biobanks: what it means to cancer patients.

Pellegrini I, Chabannon C, Mancini J, Viret F, Vey N, Julian-Reynier C.

Health Expect. 2014 Aug;17(4):523-33. doi: 10.1111/j.1369-7625.2012.00781.x. Epub 2012 Apr 19.

PMID:
22512791
13.

Two-stage hepatectomy: who will not jump over the second hurdle?

Turrini O, Ewald J, Viret F, Sarran A, Goncalves A, Delpero JR.

Eur J Surg Oncol. 2012 Mar;38(3):266-73. doi: 10.1016/j.ejso.2011.12.009. Epub 2012 Jan 12.

PMID:
22244437
14.

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M.

Oncologist. 2011;16(11):1557-64. doi: 10.1634/theoncologist.2011-0141. Epub 2011 Oct 20.

15.

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.

Oberic L, Viret F, Baey C, Ychou M, Bennouna J, Adenis A, Peiffert D, Mornex F, Pignon JP, Celier P, Berille J, Ducreux M.

Radiat Oncol. 2011 Sep 26;6:124. doi: 10.1186/1748-717X-6-124.

16.

[Predictive factors of tumour response after neoadjuvant chemoradiation for locally advanced rectal cancer and correlation of these factors with survival].

Farnault B, Moureau-Zabotto L, de Chaisemartin C, Esterni B, Lelong B, Viret F, Giovannini M, Monges G, Delpero JR, Bories E, Turrini O, Viens P, Resbeut M.

Cancer Radiother. 2011 Jul;15(4):279-86. doi: 10.1016/j.canrad.2011.01.005. Epub 2011 Apr 22. French.

PMID:
21515083
17.

Genome profiling of pancreatic adenocarcinoma.

Birnbaum DJ, Adélaïde J, Mamessier E, Finetti P, Lagarde A, Monges G, Viret F, Gonçalvès A, Turrini O, Delpero JR, Iovanna J, Giovannini M, Birnbaum D, Chaffanet M.

Genes Chromosomes Cancer. 2011 Jun;50(6):456-65. doi: 10.1002/gcc.20870. Epub 2011 Mar 15.

PMID:
21412932
18.

Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?

Moureau-Zabotto L, Viret F, Giovaninni M, Lelong B, Bories E, Delpero JR, Pesenti C, Caillol F, de Chaisemartin C, Minsat M, Monges G, Sarran A, Resbeut M.

J Surg Oncol. 2011 Jul 1;104(1):66-71. doi: 10.1002/jso.21866. Epub 2011 Jan 15.

PMID:
21240983
19.

Consent for biobanking: assessing the understanding and views of cancer patients.

Mancini J, Pellegrini I, Viret F, Vey N, Daufresne LM, Chabannon C, Julian-Reynier C.

J Natl Cancer Inst. 2011 Jan 19;103(2):154-7. doi: 10.1093/jnci/djq498. Epub 2010 Dec 20.

20.

Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival.

Barbier L, Turrini O, Grégoire E, Viret F, Le Treut YP, Delpero JR.

HPB (Oxford). 2011 Jan;13(1):64-9. doi: 10.1111/j.1477-2574.2010.00245.x. Epub 2010 Dec 7. Erratum in: HPB (Oxford). 2011 Dec;13(12):899.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk